Factor VIIa Inhibitor PCI-27483

A reversible small-molecule inhibitor of activated factor VII (factor VIIa) with potential antineoplastic and antithrombotic activities. FVII, a serine protease, becomes activated (FVIIa) upon binding with TF forming the FVIIa/TF complex, which induces intracellular signaling pathways by activating protease activated receptor 2 (PAR-2). Upon subcutaneous administration, factor VIIa inhibitor PCI-27483 selectively inhibits factor FVIIa in the VIIa/TF complex, which may prevent PAR-2 activation and PAR2-mediated signal transduction pathways, thereby inhibiting tumor cell proliferation, angiogenesis, and metastasis of TF-overexpressing tumor cells. In addition, this agent inhibits both the extrinsic and intrinsic coagulation cascades, preventing blood clot formation. TF, a blood protein overexpressed on the cell surface of a variety of tumor cell types, may correlate with poor prognosis; PAR-2 (also known as thrombin receptor-like 1) is a G protein-coupled receptor (GPCR) and a protease-activated receptor. (NCI Thesaurus)

YOU MAY ALSO LIKE

Factor VIIa Activity Measurement

The determination of the amount of the biological activity of factor VIIa in a sample.

Factor VII Measurement

The determination of the amount of factor VII present in a sample.

Factor VII Activity Measurement

The determination of the amount of the biological activity of factor VII in a sample.

Factor V Measurement

The determination of the amount of factor V present in a sample.

Factor V Leiden Mutation

An abnormality that refers to mutation of factor V Leiden, which is a variant of human factor V. It results in thrombophilia,…

Factor V Leiden Measurement

The determination of the amount of Factor V Leiden present in a sample.